Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (GB:0NIQ)
LSE:0NIQ
Earnings Data
Report Date
Apr 16, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.1Last Year’s EPS
1.01Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Jan 28, 2025
|% Change Since: -2.82%
|Next Earnings Date:Apr 16, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong order intake growth and free cash flow improvement, but also highlighted significant challenges in the equipment business and the Chinese market. Profitability was maintained at robust levels despite slight declines compared to the previous year.Company Guidance
The Sartorius and Sartorius Stedim Biotech Conference Call on the Preliminary Results for 2024 provided an extensive overview of the company's performance and outlook. Key metrics discussed included a 0.1% increase in sales to €3.4 billion in constant currencies, and an underlying EBITDA margin of 28% with an absolute value of €945 million. Order intake was double-digit ahead of the prior year, with a significant 13% increase in bioprocess solutions, reaching €2.7 billion. The regional performance indicated a 5.5% growth in EMEA, while the Americas saw a decline due to a focus on life sciences and pharma, and Asia-Pacific experienced a 1.4% growth, largely impacted by China. The company's efficiency program delivered over €100 million in savings, contributing to a robust free cash flow of €550 million, doubling from the previous year. The outlook for 2025 anticipates moderate profitable growth above market rates, with a cautious approach to market recovery dynamics.Order Intake Growth
Order intake for Bioprocess Solutions increased by approximately 13% in constant currencies to €2.7 billion, with a strong finish in Q4 driven by consumables.
Healthy Free Cash Flow
Free cash flow doubled compared to the previous year, from €271 million to €550 million, due to effective working capital initiatives and tighter CapEx management.
Regional Growth in EMEA
The EMEA region exhibited strong performance with an overall growth of 5.5% driven by recurring business.
Biosimilars and Cell and Gene Therapy Growth
Advanced therapies and biosimilars are expected to see even higher growth rates within the biopharma market, contributing to Sartorius' future growth.
---
GB:0NIQ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0NIQ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 28, 2025 | €198.80 | €222.00 | +11.67% |
| Oct 17, 2024 | €179.94 | €200.56 | +11.46% |
| Jul 18, 2024 | €197.20 | €199.20 | +1.01% |
| Apr 18, 2024 | €255.40 | €228.98 | -10.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sartorius AG (GB:0NIQ) report earnings?
Sartorius AG (GB:0NIQ) is schdueled to report earning on Apr 16, 2025, TBA Not Confirmed.
What is Sartorius AG (GB:0NIQ) earnings time?
Sartorius AG (GB:0NIQ) earnings time is at Apr 16, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sartorius AG stock?
The P/E ratio of Sartorius is N/A.
What is GB:0NIQ EPS forecast?
GB:0NIQ EPS forecast for the fiscal quarter 2025 (Q1) is 1.1.
---